Cancer Genetics Inc. (NASDAQ:CGIX) fell 3.4% on Friday . The stock traded as low as $1.97 and last traded at $2.00, with a volume of 74,460 shares traded. The stock had previously closed at $2.07.

Several brokerages have weighed in on CGIX. Zacks Investment Research cut Cancer Genetics from a “buy” rating to a “hold” rating in a report on Monday, May 16th. Aegis upped their target price on Cancer Genetics from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 15th.

The company’s market capitalization is $27.30 million. The company has a 50-day moving average of $2.07 and a 200-day moving average of $2.44.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. The company earned $6.10 million during the quarter, compared to analyst estimates of $6.95 million. Cancer Genetics’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.44) EPS. On average, equities research analysts anticipate that Cancer Genetics Inc. will post ($1.26) earnings per share for the current year.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.